11:00am - 11:30am ET

State of the industry briefing - Tim Hunt: CEO, ARM

11:30am - 12:25pm ET

Next-gen viral vectors take the spotlight as safety frets persist

12:30pm - 1:25pm ET

The future is now: CGTx innovation, challenges, and perspectives

1:30pm - 2:25pm ET

The need for speed in CGT manufacturing: Increasing throughput and efficiency through process innovation, automation, and digitization

2:30pm - 3:25pm ET

The price is right: Approvals & market access in 2023

3:30pm - 4:30pm ET

Moving clinical development forward in 2023

11:00am - 11:30am ET

State of the industry briefing - Tim Hunt: CEO, ARM

ARM’S annual update on progress in the CGTx Sector

In this session you will hear about:

  • Scientific advances in cell & gene therapy
  • Recent and anticipated approvals and clinical milestones
  • The CGTx investment landscape
  • Patient access and affordability
Tim Hunt
Tim Hunt
CEO
ARM
Tim Hunt
Anshul Mangal
President
Project Farma & Precision ADVANCE
moderator
11:30am - 12:25pm ET

Next-gen viral vectors take the spotlight as safety frets persist

Established AAVs have helped birth a new era of drugs, while also underscoring safety threats that can torpedo clinical-stage development projects. Now a new generation of vectors are coming along to keep the development work on track, with improvements in vector tech that promise widespread adoption — if it works.

Nicole Paulk
Nicole Paulk
Assistant Professor, Affiliate
UCSF
Eric Crombez
Eric Crombez
Chief Medical Officer & Executive Vice President
Ultragenyx
Federico Mingozzi
Federico Mingozzi
Chief Science & Technology Officer
Spark Therapeutics
Sam Hopkins
Sam Hopkins
SVP, Sector Lead
AskBio
John Carroll
John Carroll
Editor & Founder
Endpoints News
moderator
12:30pm - 1:25pm ET

The future is now: CGTx innovation, challenges, and perspectives

Despite recent economic challenges, innovators are working tirelessly to develop cutting-edge advancements that have the potential to revolutionize patient care. From state-of-the-art technologies to groundbreaking scientific breakthroughs, the need for increased efficiency, enhanced safety, and shorter time-to-market has never been more critical. Join our panel of experts as they discuss the latest healthcare advancements, their transformative impact on patient outcomes, and strategies for accelerating the delivery of these life-changing treatments.

James Wilson
James Wilson
Professor, Medicine and Pediatrics & Director, Gene Therapy Program
University of Pennsylvania
Bruce Levine
Bruce Levine
Barbara and Edward Netter Professor, Cancer Gene Therapy
University of Pennsylvania
Deborah Phippard
Deborah Phippard
CSO
Precision for Medicine
Kiran Reddy
Kiran Reddy
Sr. Managing Director
Blackstone
Anshul Mangal
Anshul Mangal
President
Project Farma & Precision ADVANCE
moderator
1:30pm - 2:25pm ET

The need for speed in CGT manufacturing: Increasing throughput and efficiency through process innovation, automation, and digitization

Manufacturing is one of the biggest obstacles for cell and gene therapy companies, requiring significant investment and highly specialized processes that can be very complex and difficult to develop and maintain in-house. With the paradigm shift from ‘Make’ to ‘Buy’ for advanced therapy manufacturing, innovator companies need to carefully consider their choice of CDMO partner for their manufacturing needs to ensure adequate, on-time capacity for the patients who desperately need these life-changing therapies.

John Lee
John Lee
SVP, Cell Therapy Manufacturing
Center for Breakthrough Medicines
Jeet Sarkar
Jeet Sarkar
VP, Information Technology
Center for Breakthrough Medicines
Joerg Ahlgrimm
Joerg Ahlgrimm
CEO
SK Pharmteco
Sumit Verma
Sumit Verma
SVP, Global Strategic Manufacturing
Iovance Biotherapeutics, Inc.
Chris Stevens
Chris Stevens
Chief Patient Supply Officer
Spark Therapeutics, Inc.
Audrey Greenberg
Audrey Greenberg
Co-Founder & CBO
Center for Breakthrough Medicines
moderator
2:30pm - 3:25pm ET

The price is right: Approvals & market access in 2023

Payers and purchasers continue to grapple with complex discussions around drug pricing, duration of effect, and reimbursement mechanisms, which are creating barriers to access. In this session, our experts share their insights on how stakeholders across the treatment development continuum can collaborate to develop evidence and streamline these processes to enhance access.

Christopher Kurtz
Christopher Kurtz
CMO
Kate Therapeutics
Francesca Cook
Francesca Cook
VP, Market Access
RegenXBio
Oswald Bentinck
Oswald Bentinck
VP, Global Head of Value & Access
Rocket Pharma
Francis Pang
Francis Pang
SVP, Global Market Access
Orchard Therapeutics
Phil Cyr
Phil Cyr
SVP
Precision Value & Health
moderator
3:30pm - 4:30pm ET

Moving clinical development forward in 2023

Clinical trials are essential for developing innovative and life-saving treatments for patients. However, the process can be challenging and complex for developers. In this session, our panel of experts will explore the latest strategies for navigating the complexities of clinical trial execution and share valuable insights into the cutting-edge advancements that are driving the future of healthcare innovation.

Kanya Rajangam
Kanya Rajangam
CMO & Head of Research & Development
Senti Bio
Robert Ang
Robert Ang
CEO
Vor Bio
Albert Seymour
Albert Seymour
President & CEO
Homology Medicines
Cristina Musselli
Cristina Musselli
Head of Clinical Development
Abata Therapeutics
Teresa Pokladowski
Teresa Pokladowski
Regional VP, Clinical Business Solutions
Precision for Medicine
moderator

Register to watch recordings

No cost to register, subject to confirmation. By registering for this event, you accept that you may receive direct communication from the sponsor(s). If you are experiencing problems with your registration, please contact our support team.